Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABR Combined With Camrelizumab in Oligometastatic GI Cancer
NCT04625894Phase 1Unknown
- Sponsor
- Fudan University
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of camrelizumab in Gastric carcinoma (GC), colorectal carcinoma (CRC) and hepatocellular carcinoma (HCC), sponsored by Fudan University. Primary endpoint: Dose-limiting toxicities at 2 years. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
Gastric carcinoma (GC)colorectal carcinoma (CRC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04625894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04625894.